Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CLINDAGEL is a topical gel formulation of clindamycin phosphate approved in 2000 for treating acne vulgaris and bacterial vaginosis. The mechanism of action in acne is unknown, but the product delivers a broad-spectrum antibiotic to affected skin and mucosal surfaces. It represents a mature, well-established dermatology/gynecology franchise.
Mature product approaching loss of exclusivity with minimal Part D utilization signals consolidation of brand team and transition focus to generic erosion management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers
Worked on CLINDAGEL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CLINDAGEL shows zero linked job openings, reflecting its mature, stable status with minimal commercial expansion or development needs. Career opportunities are limited to retained brand stewardship, payer management, and cost-mitigation roles as exclusivity erodes.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo